Rapacuronium
Rapacuronium bromide | |
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | none |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Not applicable |
Protein binding | Variable |
Metabolism |
Hydrolyzed to active metabolites CYP system not involved |
Biological half-life | 141 minutes (mean) |
Excretion | Renal and fecal |
Identifiers | |
| |
Synonyms | [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate |
CAS Number | 156137-99-4 |
PubChem (CID) | 5311398 |
DrugBank | DB04834 |
ChemSpider | 4470889 |
ChEMBL | CHEMBL1201352 |
ECHA InfoCard | 100.211.226 |
Chemical and physical data | |
Formula | C37H61N2O4+ |
Molar mass | 597.891 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Rapacuronium (Raplon) is a rapidly acting, non-depolarizing neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.
Due to risk of fatal bronchospasm it was withdrawn from the United States market by Organon on March 27, 2001, less than 2 years after its FDA approval in 1999.[1]
References
- ↑ Shapse, Deborah (March 27, 2001). "Voluntary Market Withdrawal" (PDF). (10.8 KiB). Organon International. Retrieved on 2007-04-02.
This article is issued from Wikipedia - version of the 11/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.